Clinical trials: Metabolic Control
Dyslipidemias
Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled
To examine variation rate of Non-HDL with KI1106 comparison Atorvastatin monotherapy.
- Trial name
- NCT03482180
- Testing
- KI1106 4g, QD, Atorvastatin Calcium 20mg, QD
- Volunteers
- 215 people
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
Osteoporosis, Vitamin D Deficiency
A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
The purpose of this study is to test the safety, tolerability, and effectiveness of an investigational drug and dietary supplement to reduce the risk of vitamin D insufficiency and deficiency during treatment of osteoporosis in…
- Trial name
- NCT00092079
- Testing
- MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks
- Volunteers
- 652 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus Type 2
A Study of RO6807952 in Patients With Diabetes Mellitus Type 2
This randomized, placebo-controlled, multiple ascending dose study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6807952. Patients will receive multiple weekly subcutaneous doses of RO6870952.
- Trial name
- NCT01358929
- Testing
- RO6807952
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus
Multiple Ascending Dose Study in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics following ascending multiple doses of AMG 876 in subjects with type 2 diabetes.
- Trial name
- NCT01856881
- Testing
- AMG 876
- Where
- 6 sites in United States
- Volunteers
- 86 people
- Sponsor
- Amgen
Foot Ulcer, Diabetic
A Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor for Induction of Healing of Diabetic Foot Ulcers
This is a Phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of three different doses of topically applied telbermin in subjects ≥ 18 years old with diabetic foot ulcers.
- Trial name
- NCT00351767
- Testing
- telbermin
- Volunteers
- 170 people
- Sponsor
- Genentech, Inc.
Diabetes Mellitus
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to determine the efficacy and safety of SYR-472, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin.
- Trial name
- NCT00760344
- Testing
- SYR-472, Sitagliptin
- Where
- 112 sites in United States, Mexico
- Volunteers
- 386 people
- Sponsor
- Takeda
Hypercholesterolemia, Coronary Disease
Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)
This study will evaluate patients who have coronary heart disease to determine if an investigational drug will further lower cholesterol when taken in combination with an approved cholesterol lowering medication.
- Trial name
- NCT00092599
- Testing
- MK0653, ezetimibe
- Volunteers
- 410 people
- Sponsor
- Organon and Co
Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy
The purpose of this study is to evaluate the efficacy and safety of AD-233A, AD-233B, AD-233C and/or AD-233D combination therapy
- Trial name
- NCT07816198
- Testing
- AD-233A, AD-233B, AD-233C
- Volunteers
- 354 people
- Sponsor
- Addpharma Inc.
Type 2 Diabetes Mellitus, Metabolic Syndrome
Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome
This is a Phase 2, multi-center, double-blind, placebo-controlled study of the safety and effect of PBI-4050 at doses ranging from 400 mg to 1200 mg on relevant biomarkers in subjects with inadequately-controlled T2DMS on stable…
- Trial name
- NCT03081598
- Testing
- PBI-4050
- Where
- 11 sites in Canada
- Volunteers
- 104 people
- Sponsor
- Liminal BioSciences Ltd.
Hypercholesterolemia
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
Study objective is to evaluate the level of control of hypercholesterolemia in Egypt in patients taking lipid lowering agents for at least 3 months ( with no drug change or dose amendment for a minimum of 6 weeks).
- Trial name
- CEPHEUS (NCT01604733)
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
This study will examine the safety and efficacy of albiglutide in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes.
- Trial name
- NCT00976391
- Testing
- albiglutide + insulin glargine, insulin glargine + preprandial lispro insulin
- Where
- 209 sites in United States, Brazil and 12 more
- Volunteers
- 586 people
- Sponsor
- GlaxoSmithKline
Atherosclerosis
A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients
The primary objective of this study is to examine the effects of SB-480848 on plasma lipoprotein associated phospholipase A2 (Lp-PLA2) activity in dyslipidemic patients during a 4-week treatment with SB-480848.
- Trial name
- NCT00734032
- Testing
- SB480848 40mg EC Tablet, SB480848 80mg EC Tablet, SB480848 160mg EC Tablet
- Where
- 7 sites in Japan
- Volunteers
- 107 people
- Sponsor
- GlaxoSmithKline
Obesity, Overweight
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric…
- Trial name
- ADVANCE (NCT06672549)
- Testing
- Orforglipron
- Where
- 116 sites in United States, Belgium and 11 more
- Volunteers
- 125 people
- Sponsor
- Eli Lilly and Company
Aging
A Study to Evaluate Efficacy of Dietary Ingredient in Vitality and Metabolic Factors in Healthy Individuals
The present study is a randomized, placebo-controlled, feasibility study to evaluate efficacy of dietary ingredients in vitality \& metabolic factors in healthy individuals.
- Trial name
- NCT06188949
- Testing
- Dolichos biflorus (Horsegram) seed extract, Carica papaya leaves extract
- Where
- 2 sites in India
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Diabetes Mellitus, Type 2
A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
This study is designed to examine the efficacy and safety of 2 dose levels of weekly subcutaneously injected albiglutide compared with placebo and an open label reference arm of daily subcutaneous injections of liraglutide, in…
- Trial name
- NCT01733758
- Testing
- Albiglutide 30 mg weekly, Albiglutide 50 mg weekly, Liraglutide 0.9 mg daily
- Where
- 74 sites in Japan
- Volunteers
- 494 people
- Sponsor
- GlaxoSmithKline
Diabetes Melliuts, Type 2
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
This is a trial in obese subjects who have poor lipid control with and without Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics of multiple doses of PF-05231023
- Trial name
- NCT01673178
- Testing
- 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023
- Where
- 17 sites in United States
- Volunteers
- 107 people
- Sponsor
- Pfizer
Obesity & Overweight
A Study of SGB-7342 in Subjects With Obesity or Overweight
The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.
- Trial name
- NCT07324850
- Testing
- SGB-7342
- Volunteers
- 45 people
- Sponsor
- Suzhou Sanegene Bio Inc.
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382
- Trial name
- NCT03235050
- Testing
- MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose
- Where
- 119 sites in United States, Bulgaria and 6 more
- Volunteers
- 834 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics and pharmacodynamics of single escalating doses of PF-05231023.
- Trial name
- NCT01285518
- Testing
- PF-05231023
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- Pfizer
Insulin Resistance
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (PEG)-BHD1028
Adiponectin has been known to play critical roles in various physio-regulatory processes, and adiponectin deficiency may contribute to insulin resistance. (PEG)-BHD1028 was developed as an agonist of adiponectin receptors.
- Trial name
- NCT06563115
- Testing
- (PEG)-BHD1028 Single Ascending Dose, (PEG)-BHD1028 Multiple Ascending Dose
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- EncuraGen, Inc